Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 20;7(71):eabo1303.
doi: 10.1126/sciimmunol.abo1303. Epub 2022 May 20.

Understanding T cell responses to COVID-19 is essential for informing public health strategies

Santosha Vardhana  1   2   3 , Lance Baldo  4 , William G Morice 2nd  5 , E John Wherry  6   7   8
Affiliations
Review

Understanding T cell responses to COVID-19 is essential for informing public health strategies

Santosha Vardhana et al. Sci Immunol. .

Abstract

Durable T cell responses to SARS-CoV-2 antigens after infection or vaccination improve immune-mediated viral clearance. To date, population-based surveys of COVID-19 adaptive immunity have focused on testing for IgG antibodies that bind spike protein and/or neutralize the virus. Deployment of existing methods for measuring T cell immunity could provide a more complete profile of immune status, informing public health policies and interventions.

PubMed Disclaimer

Conflict of interest statement

S.V. is a consultant or advisor for Immunai and ADC Therapeutics. L.B. declares employment, equity interest, and a leadership role at Adaptive Biotechnologies. W.G.M. has no competing interests to declare. E.J.W. is a consultant or advisor for Merck, Marengo, Janssen, Related Sciences, Synthekine, and Surface Oncology and a founder of Surface Oncology, Arsenal Biosciences, and Danger Bio. E.J.W. is an inventor on a patent (U.S. Patent number 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer.

Figures

Fig. 1.
Fig. 1.. Schematic of molecular and cellular technologies for the evaluation of T cell responses to SARS-CoV-2.
Molecular assay workflow (left) as shown is modeled on Adaptive Biotechnologies’ immunoSEQ platform (38). Genomic DNA and a control synthetic immune repertoire template (not shown in the illustration) are PCR-amplified in parallel using primers specific for V-J sequences and subsequently for introduction of sequencing adapters and barcodes. NGS is performed, and the generated sequences are fed to the binary classifier to obtain the final results. In the classifier and threshold call graph, the enhanced sequences count (y axis) refers to the number of identified public SARS-CoV-2–associated TCRs versus the total number of unique rearrangements (x axis) within a given sample. The diagnostic model threshold is set to a high predetermined specificity against a set of holdout negative controls not used in training. Cellular assays (right) require viable PBMCs and can use either ex vivo stimulation for functional readouts, as in ELISpots and ICS/AIM assays, versus direct labeling with HLA- and peptide-specific tetramers. ICS/AIM and tetramer-based approaches involve acquisition of samples by a flow cytometer.
See this image and copyright information in PMC

References

    1. Jones JM, Stone M, Sulaeman H, Fink RV, Dave H, Levy ME, Germanio CD, Green V, Notari E, Saa P, Biggerstaff BJ, Strauss D, Kessler D, Vassallo R, Reik R, Rossmann S, Destree M, Nguyen K-A, Sayers M, Lough C, Bougie DW, Ritter M, Latoni G, Weales B, Sime S, Gorlin J, Brown NE, Gould CV, Berney K, Benoit SJ, Miller MJ, Freeman D, Kartik D, Fry AM, Azziz-Baumgartner E, Hall AJ, Neil AM, Gundlapalli AV, Basavaraju SV, Gerber SI, Patton ME, Custer B, Williamson P, Simmons G, Thornburg MJ, Kleinman S, Stramer SL, Opsomer J, Busch MP, Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020-May 2021. JAMA 326, 1400–1409 (2021). - PMC - PubMed
    1. Phillips N, The coronavirus is here to stay - Here’s what that means. Nature 590, 382–384 (2021). - PubMed
    1. C Pulliam JR, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J, Mlisana K, Moultrie H, Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv 2021.11.11.21266068 [Preprint]. 2 December 2021. 10.1101/2021.11.11.21266068. - DOI - PMC - PubMed
    1. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin J-B, Olsson A, Llewellyn-Lacey S, Kamal H, Bogdanovic G, Muschiol S, Wullimann DJ, Kammann T, Emgård J, Parrot T, Folkesson E; Karolinska COVID- Study Group, Rooyackers O, Eriksson LI, Henter J-I, Sönnerborg A, Allander T, Albert J, Nielsen M, Klingström J, Gredmark-Russ S, Björkström NK, Sandberg JK, Price DA, Ljunggren H-G, Aleman S, Buggert M, Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158–168.e14 (2020). - PMC - PubMed
    1. Rijkers G, Murk J-L, Wintermans B, van Looy B, van den Berge M, Veenemans J, Stohr J, Reusken C, van der Pol P, Reimerink J, Differences in antibody kinetics and functionality between severe and mild severe acute respiratory syndrome coronavirus 2 infections. J Infect Dis 222, 1265–1269 (2020). - PMC - PubMed

Publication types

Substances